Aztreonam (Synonyms: SQ 26,776) |
Catalog No.GC14670
One-Click Copy Product Info
|
Aztreonam is a monobactam antibiotic characterized by high stability against β-lactamases.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 78110-38-0
Sample solution is provided at 25 µL, 10mM.
Aztreonam is a monobactam antibiotic characterized by high stability against β-lactamases. Aztreonam inhibits bacterial cell wall synthesis by binding with high affinity to penicillin-binding protein 3 (PBP3) on the cell membranes of susceptible aerobic gram-negative bacteria. Aztreonam can be used in research related to the treatment of urinary tract infections, lower respiratory tract infections, sepsis, intra-abdominal infections, skin and soft tissue infections, and gynecological infections caused by aerobic gram-negative bacteria[1-4].
In vitro, Aztreonam (0.25–2mg/mL) was co-incubated with IFN-γ (50ng/mL) and A549 lung epithelial cells for 1–4 days. Aztreonam did not alter the ability of IFN-γ to induce CD54 expression[5]. Aztreonam (0.0125-6.25mg/L) was incubated with the mouse macrophage cell line CA1SL1 for 2 hours. Aztreonam significantly enhanced the bactericidal activity of macrophages against Escherichia coli S615, Pseudomonas aeruginosa K1, Klebsiella pneumoniae 12, and Serratia marcescens US5[6].
In vivo, Aztreonam (28mg/kg/day; once daily) was intraperitoneally injected into BALB/c mice for 14 days, Aztreonam increased IL-1 production and natural killer cell activity in mouse serum. Aztreonam (57mg/kg/day; once daily) was intraperitoneally injected into BALB/c mice for 7 days, Aztreonam enhanced natural killer cell activity[7]. Aztreonam (6.25-100mg/kg/day) was administered orally or subcutaneously to Swiss mice for 10 days, Aztreonam (>25mg/kg/day; oral) significantly increased cecal weight and reduced colonization resistance against Candida albicans. Both oral and subcutaneous administration of Aztreonam caused a dose-dependent decrease in the number of aerobic gram-negative rods in feces[8].
References:
[1] Johnson DH, Cunha BA. Aztreonam. Med Clin North Am. 1995 Jul;79(4):733-43.
[2] Bush K. Past, present, and future perspectives on aztreonam and avibactam. Expert Rev Anti Infect Ther. 2025 May;23(5):277-290.
[3] Neu HC. Aztreonam: the first monobactam. Med Clin North Am. 1988 May;72(3):555-66.
[4] Shirley M. Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms. Drugs. 2026 Jan;86(1):79-91.
[5] Brooks BM, Hart CA, Coleman JW. Differential effects of beta-lactams on human IFN-gamma activity. J Antimicrob Chemother. 2005 Dec;56(6):1122-5.
[6] Iida-Tanaka K, Tanaka T, Irino S, et al. Enhanced bactericidal action of mouse macrophages by subinhibitory concentrations of monobactams. J Antimicrob Chemother. 1986 Aug;18(2):239-50.
[7] Ortega E, de Pablo MA, Gallego AM, et al. Effects of aztreonam on natural immunity in mice. Int J Antimicrob Agents. 1999 Sep;13(1):41-6.
[8] van Ogtrop ML, Guiot HF, Mattie H, et al. Modulation of the intestinal flora of mice by treatment with aztreonam and tigemonam. Antimicrob Agents Chemother. 1991 May;35(5):983-5.
| Cell experiment [1]: | |
Cell lines | A549 human lung epithelial cell line |
Preparation Method | IFN-γ (50ng/mL) was incubated with or without Aztreonam (0.25-2mg/mL) at 37°C for 1-4 days. IFN-γ activity was assayed by induction of CD54 on A549 cells. |
Reaction Conditions | 0.25-2mg/mL; 1-4 days |
Applications | Aztreonam had the least effect on IFN-γ activity, with no significant inhibition observed compared to other β-lactams. |
| Animal experiment [2]: | |
Animal models | Female specific-pathogen-free Swiss mice |
Preparation Method | Mice were given Aztreonam orally or subcutaneously in single daily doses 6.25-100mg/kg/day for 10 days. Several parameters of intestinal ecology were measured. |
Dosage form | 6.25-100mg/kg; orally or subcutaneously; single daily doses for 10 days |
Applications | Oral treatment with high doses of Aztreonam (≥25mg/kg/day) led to a significant increase in relative cecal weight and reduced colonization resistance for Candida albicans, while subcutaneous administration did not. Both oral and subcutaneous administration caused a dose-dependent decrease in the number of aerobic gram-negative rods in feces. |
References: | |
| Cas No. | 78110-38-0 | SDF | |
| Synonyms | SQ 26,776 | ||
| Chemical Name | 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid | ||
| Canonical SMILES | CC1C(C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N | ||
| Formula | C13H17N5O8S2 | M.Wt | 435.43 |
| Solubility | ≥ 18.9mg/mL in DMSO, ≥ 10.24 mg/mL in Water with ultrasonic | Storage | Store at 0-6°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2966 mL | 11.4829 mL | 22.9658 mL |
| 5 mM | 459.3 μL | 2.2966 mL | 4.5932 mL |
| 10 mM | 229.7 μL | 1.1483 mL | 2.2966 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)